Slomovitz on Tisotumab Vedotin’s Promise for Cervical Cancer
Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Get the facts about basal cell carcinoma (BCC), the most common form of skin cancer, along with answers to your questions and images.
NCI-CONNECT partnered with the Central Brain Tumor Registry of the United States (CBTRUS) to share up-to-date patterns of incidence, prevalence, and survival for 12 rare…
Capecitabine or XELOX failed to improve OS at 2 years vs fluorouracil/cisplatin as DCRT in inoperable locally advanced esophageal squamous cell carcinoma.
ASH Announces 24 Institutions Selected for Duffy Status Health Equity Project
Moderate to vigorous aerobic and resistance exercise may improve vascular function among cancer survivors, according to findings presented at American Association for Cancer Research Annual…
Supported by an independent educational grant from Servier. Join us for an interactive a nd engaging symposium that takes a deep dive into the latest…
AbstractBackground. Prior work assessing disparities in cancer outcomes has relied on regional socioeconomic metrics. These metrics average data across man
The phase II DESTINY-PanTumor01 trial showed activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with unresectable or metastatic solid tumors that have specific activating HER2 mutations.
With active surveillance (also known as “watch and wait” or “watchful waiting”), patients do not receive any anti-lymphoma treatments but their health and disease are…
Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure. To access this subscriber-only content please log in…